Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9560	Companies
188851	Keywords
120589	Articles
100789	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 05/06/2024 at 14:30, 1 year 7 months ago

Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
Jaguar Health, Inc. establishes Investigational New Animal Drug (INAD) file with FDA for crofelemer to treat canine diarrhea. Conditional approval received for chemotherapy-induced diarrhea (CID) in dogs

Crofelemer FDA Approval Jaguar Health Inc. Canine Diarrhea Investigational New Animal Drug
BRIEF

published on 04/29/2024 at 14:35, 1 year 7 months ago

Jaguar Health, Inc. Sponsors Pediatric Gastroenterology Conference and MVID Panel in Abu Dhabi

Napo Pharmaceuticals Crofelemer Jaguar Health MVID Pediatric Gastroenterology
BRIEF

published on 04/29/2024 at 14:35, 1 year 7 months ago

Jaguar Health, Inc. sponsorise la conférence de gastroentérologie pédiatrique et le panel MVID à Abu Dhabi

Crofelemer Santé Jaguar MVID Napo Pharmaceutique Gastro-entérologie Pédiatrique
PRESS RELEASE

published on 04/29/2024 at 14:30, 1 year 7 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's plant-based drug crofelemer granted Orphan Drug Designation for MVID and SBS, with proof-of-concept studies planned for 2024. Napo sponsors Elite Ped-GI Congress panel discussion on rare digestive disorders

Crofelemer Jaguar Health Orphan Drug Designation MVID SBS
BRIEF

published on 04/22/2024 at 14:50, 1 year 7 months ago

Jaguar Health's Napo Pharmaceuticals to Exhibit at ONS Congress for Cancer Supportive Care

Patient Advocacy Cancer Supportive Care Oncology Nursing Oral Mucositis Treatment Oncology Congress
BRIEF

published on 04/22/2024 at 14:50, 1 year 7 months ago

Napo Pharmaceuticals de Jaguar Health exposera au congrès de l'ONS sur les soins de soutien contre le cancer

Soins De Soutien Contre Le Cancer Soins Infirmiers En Oncologie Traitement De La Mucite Buccale Défense Des Patients Congrès D'oncologie
PRESS RELEASE

published on 04/22/2024 at 14:45, 1 year 7 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Jaguar to launch FDA-approved Gelclair for oral mucositis in Q3 2024.

Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care ONS Congress
BRIEF

published on 04/18/2024 at 14:35, 1 year 8 months ago

Jaguar Health Strengthens its Executive Team with a New Growth Strategy Appointee

Gelclair Cancer Supportive Care Jaguar Health, Inc. Catherine Miller Collis GI Supportive Care
BRIEF

published on 04/18/2024 at 14:35, 1 year 8 months ago

Jaguar Health renforce son équipe de direction avec la nomination d'un nouveau responsable de stratégie de croissance

Gelclair Soins De Soutien Contre Le Cancer Catherine Miller Collis Jaguar Santé, Inc. Soins De Soutien Gastro-intestinaux
PRESS RELEASE

published on 04/18/2024 at 14:30, 1 year 8 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs

Cancer Treatment Jaguar Health Gelclair Oral Mucositis Catherine Miller Collis

Accesswire

Published on 12/20/2025 at 00:30, 1 day 21 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 1 day 23 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 3 hours ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 7 hours ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 2 days 8 hours ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/21/2025 at 08:55, 12 hours 50 minutes ago

Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
Published on 12/20/2025 at 16:45, 1 day 5 hours ago

Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade
Published on 12/20/2025 at 10:05, 1 day 11 hours ago

FITUR 2026 highlights the strong synergies between Germany and Spain
Published on 12/19/2025 at 22:03, 1 day 23 hours ago

EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector
Published on 12/19/2025 at 21:40, 2 days ago

IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

Les Echos

Published on 12/19/2025 at 21:57, 1 day 23 hours ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 2 days 13 hours ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 days 13 hours ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 2 days 14 hours ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 2 days 14 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE